Company profile
Longeveron Inc.
NASDAQ:LGVNBiotechnology: Pharmaceutical Preparations
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02065245 | phase1_2 | completed | 2014-03-03 | 2019-10-02 | Longeveron Inc. | AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery |
| NCT02398604 | phase1 | terminated | 2015-04-01 | 2019-03-01 | Longeveron Inc. | Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome |
| NCT04925024 | phase2 | active_not_recruiting | 2021-06-25 | 2026-06-30 | Longeveron Inc. | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. |
| NCT03525418 | phase1_2 | unknown | 2018-02-21 | 2024-06-30 | Longeveron Inc. | Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) |
| NCT05233774 | phase2 | completed | 2021-12-28 | 2023-09-29 | Longeveron Inc. | Lomecel-B Effects on Alzheimer's Disease |
FDA applications (0)
No records yet.